What is the current market size?

The **bloodstream infection testing market size** was valued at USD 1.2 billion in 2023, driven by rising sepsis cases and advanced diagnostic technologies.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by increasing healthcare investments and early detection trends.

What drives market expansion?

Key drivers include rising bloodstream infection prevalence, demand for rapid diagnostics, and adoption of molecular testing technologies.

What challenges hinder growth?

High test costs, limited access in low-income regions, and regulatory hurdles pose major challenges for the **bloodstream infection testing market**.

Which regions lead the market?

North America dominates due to advanced healthcare, followed by Europe and Asia-Pacific, where growing diagnostic awareness is emerging.

Who are the top companies?

Leading firms include Becton Dickinson, Thermo Fisher Scientific, Roche Diagnostics, and Abbott, known for innovative testing solutions.

What future opportunities exist?

Opportunities lie in point-of-care testing, AI-driven diagnostics, and rising investments in emerging markets for the **future outlook**.

How does technology impact growth?

Molecular diagnostics, PCR, and CRISPR-based assays are transforming speed and accuracy, accelerating **bloodstream infection testing market** adoption.

What is the regulatory landscape?

Regulatory approvals by FDA, CE, and WHO standards influence product development and adoption, ensuring safety and efficacy globally.

How has the pandemic affected demand?

The pandemic increased demand for rapid sepsis testing, highlighting the need for efficient diagnostics in emergency healthcare settings.

bloodstream infection testing Market Outlook, Trends & Forecast 2033

bloodstream infection testing by Application (Hospital, Clinic, Medical Center, Other), by Types (Medical Equipment, Detection Reagent), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 90

Forecast Period: 2026 - 2033

Market Size: $3200 million

CAGR: 10.5%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 90

Forecast Period: 2026 - 2033

Market Size: $3200 million

CAGR: 10.5%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

bloodstream infection testing Market Size | CAGR 10.5 Forecast 2033

bloodstream infection testing Market Outlook, Trends & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 90

Forecast Period: 2026 - 2033

Market Size: $3200 million

CAGR: 10.5%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 90

Forecast Period: 2026 - 2033

Market Size: $3200 million

CAGR: 10.5%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

bloodstream infection testing Market Overview

The bloodstream infection testing market focuses on diagnostic technologies for detecting pathogens in blood, critical for managing sepsis, bacteremia, and other systemic infections. As a cornerstone of infection control, this market is pivotal in reducing mortality rates and optimizing antimicrobial stewardship. The bloodstream infection testing market size is projected to exceed $1.8 billion by 2026, reflecting robust industry expansion driven by advanced diagnostics and evolving clinical protocols. This market forecast highlights a CAGR of 7.2% (2026–2033), underscored by rising incidence of multidrug-resistant infections and adoption of rapid molecular testing.

Loading chart…

Key drivers shaping the bloodstream infection testing market include regulatory incentives for sepsis diagnosis, integration of AI-driven pathogen identification, and decentralized testing via point-of-care (POC) platforms. North America remains the largest region due to high adoption of next-generation sequencing, while Asia-Pacific emerges as the fastest-growing market, fueled by expanding diagnostic labs and rising healthcare expenditure. Competitive dynamics are intensifying as vendors prioritize R&D investments to address unmet needs in critical care settings, ensuring the growth outlook remains optimistic across the forecast period.

Report Overview

Report Attribute	Details
Market size value in 2025	3.20 billion
Revenue forecast in 2033	7.11 billion
Growth rate	CAGR of 10.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott; BD; bioMérieux; Danaher; F. Hoffmann-La Roche; Thermo Fisher Scientific
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of immunocompromised patient populations: The increasing incidence of chronic diseases, cancer treatments, and post-transplant patients creates sustained demand for rapid bloodstream infection testing market solutions, particularly in hospital and ICU settings.

Advancements in molecular diagnostic technologies: Next-generation sequencing and PCR-based platforms are accelerating time-to-result capabilities, enabling the bloodstream infection testing market size to expand through adoption in resource-limited settings and decentralized testing hubs.

Restraints2 items

High capital expenditure for advanced diagnostic systems: The cost of implementing automated blood culture and molecular testing infrastructure limits market penetration in emerging economies with constrained healthcare budgets.

Stringent reimbursement policies in mature markets: Inconsistent coverage for rapid diagnostic tests in Medicare and private insurance frameworks in the U.S. and Europe creates financial barriers for widespread adoption.

Opportunities2 items

Expansion into lower-tier hospitals in Asia-Pacific: Urbanization and government-funded healthcare initiatives in India and Southeast Asia are unlocking new bloodstream infection testing market revenue pools through partnerships with diagnostic equipment suppliers.

Integration with antimicrobial stewardship programs: Collaborations between diagnostics firms and hospital networks to align testing protocols with antibiotic resistance data are driving innovation in test design and market differentiation.

Challenges2 items

Regulatory fragmentation across geographies: Divergent FDA, EMA, and WHO approval pathways for novel diagnostic assays delay market entry and increase development costs for bloodstream infection testing market players.

Competition from low-cost conventional methods: Legacy blood culture techniques remain entrenched in many public health systems due to cost sensitivity, despite inferior diagnostic accuracy compared to newer modalities.

Market Segmentation

Loading chart…

Application Segmentation in the bloodstream infection testing market is bifurcated into Hospital-Acquired Infections (HAI) and Community-Acquired Infections (CAI). HAIs dominate due to high prevalence in inpatient settings, stringent hospital protocols for rapid diagnostics, and the growing burden of antibiotic-resistant pathogens. This segment accounts for 60–65% of the market, driven by centralized labs and point-of-care testing in acute care facilities. Conversely, CAIs represent a growing share, fueled by outpatient testing, rising awareness of sepsis in non-hospital settings, and the adoption of portable diagnostic devices. The bloodstream infection testing segmentation by application highlights a shift toward decentralized testing for CAIs, aligning with global healthcare trends toward early intervention and cost containment.

Types Segmentation is categorized into Bacterial Bloodstream Infections (BSI) and Fungal Bloodstream Infections (BSI). Bacterial BSIs constitute the largest share (~70%), driven by the prevalence of Gram-positive and Gram-negative pathogens and the maturity of testing methods like blood cultures and PCR. Fungal BSIs, though smaller, show faster growth due to the rise in immunocompromised populations and the adoption of advanced molecular diagnostics for Candida and Aspergillus species. The market taxonomy underscores a competitive edge for technologies targeting fungal infections, as regulatory incentives and unmet clinical needs drive innovation in this segment. Both subtypes contribute to market expansion, with bacterial diagnostics maintaining dominance while fungal testing gains traction in specialty care.

bloodstream infection testing Segmentation Breakdown8 items

Application

Hospital

Clinic

Medical Center

Other

Types

Medical Equipment

Detection Reagent

Regional Insights

Loading chart…

North America dominates the bloodstream infection testing market with a 40% share, driven by advanced diagnostics adoption, robust R&D investments, and stringent regulatory frameworks. The region’s aging population and high prevalence of hospital-acquired infections further fuel demand. Europe follows with 25%, propelled by government-funded healthcare systems, rising sepsis awareness, and cross-border collaboration in diagnostic innovation. Asia Pacific is the fastest-growing region, expanding at 12% CAGR, due to urbanization, increasing healthcare infrastructure investments, and rising chronic disease incidence.

Key Regional Drivers5 items

North America: High adoption of rapid molecular diagnostics, FDA policies prioritizing sepsis management, and mature healthcare ecosystems.

Europe: EU-funded precision medicine initiatives, aging demographics, and strong reimbursement policies for infectious disease testing.

Asia Pacific: Growing public-private partnerships for diagnostic access, rising disposable incomes, and expanding hospital networks in India and China.

Latin America: Rising healthcare digitization, public health campaigns targeting neonatal sepsis, and foreign direct investments in diagnostic infrastructure.

Middle East & Africa: Government-led healthcare modernization, increasing prevalence of diabetes-related infections, and improved cold chain logistics for test kits.

The bloodstream infection testing market growth will be most pronounced in Asia Pacific through 2030, supported by a regional forecast of 15% CAGR. Strategic collaborations between diagnostics firms and local stakeholders, coupled with ICMR (Indian Council of Medical Research) initiatives, are accelerating test accessibility. Meanwhile, North America and Europe will consolidate leadership through AI-integrated testing platforms and real-world evidence programs.

Competitive Landscape

The bloodstream infection testing competitive landscape remains moderately consolidated, with global players dominating high-growth geographies and regional firms capturing niche segments. Pricing strategies vary between premium-positioned solutions emphasizing rapid diagnostics and cost-optimized assays targeting emerging markets. Key differentiation factors include regulatory approvals for multiplex PCR platforms, integration with hospital information systems, and partnerships with reference laboratories. Certifications such as ISO 15189 and CLIA compliance act as critical barriers to entry. While the top five players account for ~40% of the market, the remaining 60% is fragmented among specialty diagnostics firms and local OEMs.

Competitors prioritize M&A to strengthen assay portfolios, with recent cross-licensing agreements reducing R&D timelines for molecular-based tests. Vertical integration and localized manufacturing are common strategies to mitigate supply chain risks, though margin pressures persist due to price erosion in public healthcare tenders. Technology differentiation centers on AI-driven interpretation software and automated sample processing systems, creating switching costs for hospital clients. A key challenge lies in balancing compliance costs for evolving CLSI guidelines against pricing flexibility in price-sensitive markets.

Abbott: Regional expansion in Asia-Pacific through joint ventures with public health institutions

BD: Vertical integration of sample-to-result platforms to enhance hospital workflow efficiency

bioMérieux: Expansion of innovation pipeline targeting drug-resistant pathogen detection

Danaher: OEM tie-ups to supply rapid diagnostic components to mid-tier hospitals

F. Hoffmann-La Roche: Premium pricing strategy for fully automated molecular testing systems

Thermo Fisher Scientific: Local manufacturing hubs in Brazil and India to reduce logistics costs

Key bloodstream infection testing Companies6 items

Abbott

bioMérieux

Danaher

F. Hoffmann-La Roche

Thermo Fisher Scientific

Market Ecosystem

The bloodstream infection testing ecosystem spans upstream technology and material suppliers, midstream manufacturers and integrators, and downstream clinical end users. Value is generated through accurate, rapid diagnostic solutions that enable timely antimicrobial stewardship, with control concentrated in innovation, regulatory compliance, and end-user adoption. Interdependencies across the value chain analysis shape market dynamics from raw material sourcing to patient outcomes.

Raw material/component suppliers — provide reagents, consumables, and biocompatible materials for test kit production

OEMs/manufacturers — design and produce diagnostic platforms, including PCR systems and immunoassay devices

Technology providers — develop proprietary algorithms, AI tools, or automation for test result interpretation

System integrators — assemble and validate multi-component testing solutions for clinical deployment

Distributors/channel partners — manage logistics, compliance documentation, and product delivery to healthcare facilities

End users — implement testing workflows in hospital labs, reference labs, and point-of-care settings

Regulators/standards bodies — establish diagnostic accuracy benchmarks and approval pathways for commercialization

Control points reside in regulatory agencies dictating approval timelines and technology providers enabling differentiation. Dependency risks include supply chain disruptions for raw materials and interoperability constraints between diagnostic systems. End users face high switching costs due to workflow integration and training requirements, while midstream players mediate between innovation velocity and clinical scalability. Regional variations in diagnostic infrastructure further stratify adoption patterns across the ecosystem.

Recent Industry Insights

The bloodstream infection testing industry trends over the past 18 months have been shaped by strategic collaborations and technological advancements. Notably, partnerships between diagnostic firms and hospital networks have accelerated the adoption of rapid molecular testing, with companies like BD and BioFire Diagnostics integrating AI-driven analytics to improve detection accuracy. Mergers and acquisitions have also intensified, such as Thermo Fisher Scientific acquiring PACT Pharma to expand its sepsis diagnostic capabilities, while Cepheid launched a next-generation GeneXpert system with enhanced sensitivity for bloodstream pathogens. Regulatory bodies like the FDA have prioritized expedited approvals for rapid diagnostic tools, reflecting growing demand for time-to-result optimization. Meanwhile, the shift toward point-of-care testing (POCT) has gained momentum, driven by healthcare providers’ need for real-time decision-making in ICU settings. Funding rounds, including a $120M Series C for Adaptive Biotechnologies, highlight investor confidence in genomic sequencing solutions for antimicrobial resistance. These trends signal a market pivot toward faster, more precise diagnostics to combat rising multidrug-resistant infections.

Analyst Overview

The bloodstream infection testing market is poised for robust growth, driven by rising sepsis prevalence, hospital-acquired infections, and technological advances in diagnostic accuracy. The bloodstream infection testing market outlook remains highly attractive, with emerging markets offering untapped potential due to improving healthcare infrastructure and regulatory support. However, competitive intensity is moderate, with established players leveraging R&D and strategic partnerships to maintain dominance, while startups face barriers to entry due to high capital requirements and stringent regulatory compliance.

The long-term outlook is optimistic, fueled by demand for rapid diagnostics, AI-driven test automation, and point-of-care innovations. The innovation landscape is dynamic, with molecular and PCR-based tests gaining traction, alongside CRISPR technologies, although adoption lags in low-resource regions. Demand–supply balance is stable in developed markets but strained in emerging economies, where diagnostic infrastructure gaps persist. Key risk factors include reimbursement challenges, regulatory shifts, and antimicrobial resistance complicating test efficacy. Stakeholders must prioritize cost-efficiency, sustainability, and cross-sector collaborations to navigate these complexities and secure market share.

11 items

1. Executive Summary

2. bloodstream infection testing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global bloodstream infection testing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global bloodstream infection testing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Clinic

6.1.3. Medical Center

6.1.4. Other

6.2. Global bloodstream infection testing Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Medical Equipment

6.2.2. Detection Reagent

6.3. Global bloodstream infection testing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global bloodstream infection testing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global bloodstream infection testing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global bloodstream infection testing Market Competition by Key Manufacturers

8.1. Global bloodstream infection testing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global bloodstream infection testing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Abbott

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. BD

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. bioMérieux

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Danaher

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. F. Hoffmann-La Roche

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Thermo Fisher Scientific

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global bloodstream infection testing Market

Figure 4: Global bloodstream infection testing Market: Drivers

Figure 5: Global bloodstream infection testing Market: Challenges

Figure 6: Global bloodstream infection testing Market: Trends

Figure 7: Global bloodstream infection testing Market: Opportunity

Figure 8: Global bloodstream infection testing Market: Restraint

Figure 9: Global bloodstream infection testing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global bloodstream infection testing Market Value (USD Million) By Region

Figure 15: Global bloodstream infection testing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global bloodstream infection testing Market Value (USD Million) By Region

Figure 23: Global bloodstream infection testing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

65 items

Table 1: Market Segmentation Analysis

Table 2: Global bloodstream infection testing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global bloodstream infection testing Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global bloodstream infection testing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global bloodstream infection testing Market Value (USD Million) By Region

Table 10: Global bloodstream infection testing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global bloodstream infection testing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global bloodstream infection testing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global bloodstream infection testing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Abbott Basic Information And Sales Area

Table 31: Abbott. Products Portfolio

Table 32: BD Basic Information And Sales Area

Table 33: BD. Products Portfolio

Table 34: bioMérieux Basic Information And Sales Area

Table 35: bioMérieux. Products Portfolio

Table 36: Danaher Basic Information And Sales Area

Table 37: Danaher. Products Portfolio

Table 38: F. Hoffmann-La Roche Basic Information And Sales Area

Table 39: F. Hoffmann-La Roche. Products Portfolio

Table 40: Thermo Fisher Scientific Basic Information And Sales Area

Table 41: Thermo Fisher Scientific. Products Portfolio

Table 42: Global Market Value (USD Million) (2025-2032) By Application

Table 43: Global Market Share (%) By Application (2032)

Table 44: Global Market Value (USD Million) (2025-2032) By Types

Table 45: Global Market Share (%) By Types (2032)

Table 46: Global bloodstream infection testing Market Value (USD Million) By Region

Table 47: Global bloodstream infection testing Market Share (%) By Region (2025-2032)

Table 48: North America Market Value (USD Million) (2025-2032) By Country

Table 49: North America Market Value (USD Million) (2025-2032) By Application

Table 50: North America Market Value (USD Million) (2025-2032) By Types

Table 51: Europe Market Value (USD Million) (2025-2032) By Country

Table 52: Europe Market Value (USD Million) (2025-2032) By Application

Table 53: Europe Market Value (USD Million) (2025-2032) By Types

Table 54: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 55: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 56: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 57: South America Market Value (USD Million) (2025-2032) By Country

Table 58: South America Market Value (USD Million) (2025-2032) By Application

Table 59: South America Market Value (USD Million) (2025-2032) By Types

Table 60: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 61: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 62: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 63: Research Programs/Design For This Report

Table 64: Key Data Information From Secondary Sources

Table 65: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

bloodstream infection testing Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	3.20 billion
Revenue forecast in 2033	7.11 billion
Growth rate	CAGR of 10.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott; BD; bioMérieux; Danaher; F. Hoffmann-La Roche; Thermo Fisher Scientific
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options